Abbott has recently launched Afinion 2 analyzer, the newest generation of the Afinion test system. The Afinion 2 builds on Abbott’s heritage in diabetes care by empowering patients with information about their health that they can discuss with their providers during a single visit. The Afinion 2 analyzer is a compact, rapid, multi-assay platform that streamlines and simplifies the delivery of actionable, accurate measurements of hemoglobin A1c (HbA1c), and albumin to creatinine ratio (ACR) results at the point of care.
The system arms healthcare professionals with the information needed to make fast and accurate medical decisions – three minutes for HbA1c and five minutes for ACR – enabling healthcare professionals to dedicate more time to counseling patients within a single office visit. Along with providing rapid results, the platform now also offers all-in-one connectivity to LIS/HIS (laboratory and hospital information systems) and a sleeker, quieter experience for clinicians and patients. Healthcare professionals can use the Afinion 2 analyzer in a wide range of out-patient settings – including physician offices, clinics, community health centers, hospitals, and long-term care facilities.
Both HbA1c and ACR measurements are critical for effective diabetes management. HbA1c is a marker that clinicians can use to determine a person’s average glycemic control (blood sugar) and assess the quality of patient’s diabetes management. ACR is a marker for kidney complications that can result from poorly managed diabetes.